Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of Nivolumab in patients with non small cell lungcancer with preexisting interstitial lung disease: a retrospective study

Trial Profile

Efficacy and safety of Nivolumab in patients with non small cell lungcancer with preexisting interstitial lung disease: a retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Nov 2017 New trial record
    • 18 Oct 2017 Results assessing efficacy and safety presented at the 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top